Peroxisome Proliferator-activated Receptor γ and Cancers

Clinical Cancer Research

Volumn 9, Issue 1, 2003, Pages 1-9

  Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P21; PROTEIN P27;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CELL DIFFERENTIATION; CELL TRANSFORMATION; COLON TUMOR; HUMAN; IN VITRO STUDY; LIPOSARCOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; COLONIC NEOPLASMS; FEMALE; HUMANS; LIGANDS; MALE; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 0037235020     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Saltiel, A. R., and Olefsky, J. M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 45: 1661–1669, 1996.
2. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Wilson, T. M., and Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem., 270: 12953–12956, 1995.
3. Schoonjans, K., Staels, B., and Auwerx, J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res., 37: 907–925, 1996.
4. Lemberger, T., Desvergne, B., and Wahli, W. Peroxisome proliferatoractivated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann. Rev. Cell Dev. Biol., 12: 335–363, 1996.
5. Mangelsdorf, D. J., and Evans, R. M. The RXR heterodimers and orphan receptors. Cell, 83: 841–850, 1995.
6. Mukherjee, R., Davies, P. J. A., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, Mondon, C. E., Nadzan, A. M., Paterniti, J. R., Jr., and Heyman R. A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (Lond.), 386: 407–410, 1997.
7. Corton, J. C., Anderson, S. P., and Stauber, A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol., 40: 491–518, 2000.
8. Kodera, Y., Takeyama, K. I., Murayama, A., Suzawa, M., Masuhiro, Y., and Kato, S. Ligand-type specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. J. Biol. Chem., 275: 33201–33204, 2000.
9. Yang, W., Rachez, C., and Freedman, L. P. Discrete roles for peroxisome proliferator-activated receptor γ and retinoid X receptor in recruiting nuclear receptor coactivators. Mol. Cell. Biol., 20: 8008– 8017, 2000.
10. Wu, G. D., and Lazar, M. A. A gut check for PPAR γ Gastroenterology, 115: 1283–1285, 1998.
11. Vidal-Puig, A., Jimenez-Linan, M., Lowell, B. B., Hamann, A., Hu, E., Spiegelman, B., Flier, J. S., and Moller, D. E. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J. Clin. Investig., 97: 2553–2561, 1996.
12. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., Saladin, R., Najib, J., Laville, M., Fruehart, J. C., Deeb, S., Vidal-Puig, A., Flier, J., Briggs, M. R., Staels, B., Vidal, H., and Auwerx, J. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem., 272: 18779–18789, 1997.
13. DuBois, R. N., Gupta, R., Brockman, J., Reddy, B. S., Krakow, S. L., and Lazar, M. A. The nuclear eicosanoid receptor PPARγ is aberrantly expressed in colonic cancers. Carcinogenesis (Lond.),19: 49: 53, 1998.
14. Parks, K. S., Ciaraldi, T. P., Abrams-Carter, L., Mudaliar, S., Nikoulina, S. E., and Henry, R. R. PPARγ gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes, 46: 1230–1234, 1997.
15. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell, 1: 465–470, 1998.
16. Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S., Miyoshi, I., and Koeffler, H. P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effects against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344–3352, 1998.
17. Suh, N., Wang, Y., Honda, T., Gribble, G. W., Dmitrovsky, E., Hickey, W. F., Mave, R. A., Place, A. E., Porter, D. M., Spinella, M. J., Williams, C. R., Wu, G., Dannenberg, A. J., Flanders, K. C., Letterio, J. J., Mangelsdorf, D. J., Nathan, C. F., Nguyen, L., Porter, W. W., Ren, R. F., Roberts, A. B., Rohe, N. S., Subbaramaiah, K., and Sporn, M. B. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9- dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res., 59: 336–341, 1999.
18. Wang, Y., Porter, W. W., Suh, N., Honda, T., Gribble, G. W., Leesnitzer, L. M., Plunket, K. D., Mangelsdorf, D. J., Blanchard, S. G., Willson, T. M., and Sporn, M. B. A synthetic triterpenoid, 2-cyano-3,12-dioooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor γ. Mol. Endocrinol., 14: 1550– 1556, 2000.
19. Tontonoz, P., Hu, E., and Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell, 79: 1147–1156, 1994.
20. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev., 8: 1224–1234, 1994.
21. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A-M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., and Auwerx, J. PPAR and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 15: 5336–5348, 1996.
22. Chawla, A., Barak, Y., Nagy, L., Lio, D., Tontonoz, P., and Evans, R. M. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism. Nat. Med., 1: 48–52.
23. Jiang, C., Ting, A. T., and Seed, B. PPARγ agonists inhibit production of monocyte Inflammatory cytokines. Nature (Lond.), 391: 82–86, 1998.
24. Li, M., Pascual, G., and Glass, C. K. Peroxisome proliferatoractivate receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol., 20: 4699–4707, 2000.
25. Marx, N., Mach, F., Sauty, A., Leung, J. H., Sarafi, M. N., Ransohoff, R. M., Libby, R., Plutzky, J., and Luster, A. D. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T-cell active CXC chemokines IP10, Mig, and I-TAC in human endothelial cells. J. Immunol., 164: 6503–6508, 2000.
26. Ricote, M., Li, A. C., Wilson, T. M., Kelly, C. J., and Glass, C. K. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature (Lond.), 391: 79–82, 1998.
27. Gurnell, M., Wentworth, J. M., Agostini, M., Adams, M., Collingwood, T. N., Provenzano, C., Browne, P. O., Rajanayagam, O., Burris, T. P., Schwabe, J. W., Lazar, M. A., and Chatterjee, V. K. A dominantnegative peroxisome proliferator-activated receptor γ (PPARγ ) mutant is a constitutive repressor and inhibits PPARγ -mediated adipogenesis. J. Biol. Chem., 275: 5754–5759, 2000.
28. Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., and Jakubowski, A. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic-acid). N. Eng. J. Med., 324: 1385– 1393, 1991.
29. Warrell, R. P., de The, H., Wang, Z-Y., and Degos, L. N. Acute promyelocytic leukemia. N. Engl. J. Med., 329: 177–189, 1993.
30. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94: 237–241, 1997.
31. Demetri, G. D., Fletcher, C. D., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., and Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA, 96: 3951–3956, 1999.
32. Joyce, D., Albanese, C., and Pestell, R. G. NF-ĸβ and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev., 12: 73–90, 2001.
33. Karin, M., and Delhase, M. The Iĸβ kinase (IKK) and NF-ĸβ: key elements of proinflammatory signaling. Semin. Immunol., 12: 85–98, 2000.
34. Gupta, R. A., Brockman, J. A., Sarraf, O., Willson, T. M., and DuBois, R. N. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J. Biol. Chem., 276: 29681–29687, 2001.
35. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759–767, 1992.
36. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell, 87: 159-170, 1996.
37. Mansen, A., Guardiola-Diaz, H., Rafter, J., Branting, C., and Gustafsson, J. A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun., 222: 844–851, 1996.
38. Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., and Vidal, H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes, 46: 1319–1327, 1997.
39. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Deuchand, P., Wahli, W., Wilson, T. M., Lenhard, J. M., and Lehmann, J. M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferatoractivated receptors αand γ. Proc. Natl. Acad. Sci. USA, 94: 4318-4323, 1997.
40. Belluzzi, A., Brignola, C., Campieri, M., Pera, A., Boschi, S., and Miglioli, M. Effect of enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med., 334: 1557–1560, 1996.
41. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med., 4: 1046–1052, 1998.
42. Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 331: 1188–1193, 1994.
43. Eng, C. RET proto-oncogene in the development of human cancer. J. Clin. Oncol., 17: 380–393, 1999.
44. Marsh, D. J., Coulon, V., Lunetta, K. L., Rocca-Serra, P., Dahia, P. L., Zheng, Z., Liau, D., Caron, S., Dubove, B., Lin, A. Y., Richardson, A. L., Bonnetblanc, J. M., Bressieux, J. M., Cabarrot-Moreau, A., Chompret, A., Demange, L., Eeles, R. A., Yahanda, A. M., Fearon, E. R., Fricker, J. P., Gorlin, R. J., Hodgson, S. V., Huson, S., Lacombe, D., and Eng, C. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet., 7: 507–515, 1998.
45. Song, W-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D. C., Busque, L., Kurnit, D., Willman, C., Gerwitz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., and Gilliland, D. G. Haploinsufficiency of CBFA1 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia. Nat. Genet., 2: 166–175, 1999.
46. Hisatake, J., Ikezoe, T., Carey, M., Holden, S., Tomoyasu, S., and Koeffler, H. P. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma (troglitazone) in human prostate cancer. Cancer Res., 19: 5494–5498, 2000.
47. Girnun, G., Sarraf, P., Mueller, E., Drori, S., Gonzalez, F., and Spiegelman, B. The role of PPARγ as a tumor suppressor gene in colon carcinogenesis. Keystone Symposia: the PPARs: a transcription odyssey (Abstract). 73, 2001.
48. Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G., Ming, U. T., Baird, S. M., Thomazy, V. A., and Evans, R. M. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat. Med., 4: 1058–1061, 1998.
49. Lefebvre, A. M., Chen, I., Desreumaux, P., Najib, J., Fruchart, J. C., Geboes, K., Briggs, M., Heyman, R., and Auwerx, J. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/mice. Nat. Med., 4: 1053–1057, 1998.
50. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., d’amico, M., Pestell, R., and Ben Ze’ev, A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA, 96: 5522–5527, 1999.
51. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., daCosta, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Identification of c-myc as a target of the APC pathway. Science (Wash. DC), 281: 1509–1512, 1998.
52. Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Vogelstein, B., and Kinzler, K. W. APC mutations occur early during colorectal tumorigenesis. Nature (Lond.), 359: 235–237, 1992.
53. Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., and DuBois, R. N. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor in colorectal cancer. Proc. Natl. Acad. Sci. USA, 97: 13275–13280, 2000.
54. He, T. C., Chan, T. A., Vogelstein, B., and Kinzler, K. W. PPAR is a APC-regulated target of non-steroidal anti-inflammatory drugs. Cell, 99: 335–345, 1999.
55. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183–1188, 1994.
56. Chapple, K. S., Cartwright, E. J., Hawcroft, G., Tisbury, A., Bonifer, C., Scott, N., Windsor, A. C., Guillou, P. J., Markham, A. F., Coletta, P. L., and Hull, M. A. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am. J. Pathol., 156: 545–553, 2000.
57. Lim, H., Gupta, R. A., Paria, B. C., Ma, W. G., Moller, D. E., Morrow, J. D., DuBois, R. N., Trzaskos, J. M., and Dey, S. K. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR. Genes Dev., 13: 1561–1574, 1999.
58. Forman, B. M., Chen, J., and Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptor and. Proc. Natl. Acad. Sci. USA, 94: 4312–4317, 1997.
59. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc 716 knock-out mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803–809, 1996.
60. Thun, M. J., Namboodiri, M. M., and Heath, C. W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593–1596, 1991.
61. Jacoby, R. F., Marshall, D. J., Newton, M. A., Novakovic, K., Tutsch, K., Cole, C. E., Lubet, R. A., Kolloff, G. J., Verma, A., Moser, A. R., and Dove, W. F. Chemoprevention of spontaneous intestinal adenoma in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56: 710–714, 1996.
62. Elstner, E., Muller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., and Koeffler, H. P. Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA, 95: 8806–8811, 1998.
63. Suh, N., Wang, Y., Williams, C. R., Risingsong, R., Gihmer, T., Willson, T. M., and Sporn, M. B. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res., 59: 5671–5673, 1999.
64. Mehta, R. G., Williamson, E., Patel, M. K., and Koeffler, H. P. A ligand of peroxisome proliferator-activated receptor γ (PPARγ), retinoids and prevention of preneoplastic mammary lesions. J. Natl. Cancer Inst. (Bethesda), 92: 418–423, 2000.
65. Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P., Rosenberg, D. W., Bronson, R. T., Edelman, W., et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc. Natl. Acad. Sci. 99: 13771–13776, 2002.
66. Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G. A., Baird, S. M., Thomazy, V. A., and Evans, M. Activators of the nuclear receptor PPARγenhance color polyp formation. Nat. Med. 4: 1058– 1061, 1998.
67. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA - Cancer J. Clin., 46: 5–27, 1996.
68. Garnick, M. B. Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med., 118: 804-818, 1993.
69. Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Frigg, W. D., Zhou, X. P., Eng, C., Spiegelman, B. M., and Kantoff, P. W. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc. Natl. Acad. Sci. USA, 97: 10990–10995, 2000.
70. Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C. J., Mueller, E., Spiegelman, B. M., and Fletcher, J. A. PAX8-PPARγ1 Fusion in oncogene human thyroid carcinoma. Science (Wash. DC), 289: 1357– 1360, 2000.
71. Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S., Myoshi, I., and Koeffler, H. P. Ligand for PPARγ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3370–3375, 1998.
72. Hisatake, J., Carey, M., Holden, S., Tomoyasu, S., and Koeffler, H. P. Down-regulation of prostate-specific antigen expression by ligand for peroxisome proliferator-activated receptor gamma (troglitazone) in human prostate cancer. Cancer Res., 60: 5494–5498, 2000.
73. Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., and Evans, R. M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell, 93: 241–252, 1998.
74. Asou, H., Verbeek, W., Williamson, E., Elstner, E., Kubota, T., Kamada, N., and Koeffler, H. P. Growth inhibition of myeloid leukemiareceptor γ, and retinoids. Int. J. Oncol., 15: 1027-1093, 1999.
75. Sarraf, P., Mueller, E., Smith, W., Wright, H. M., Kum, J. B., Aaltonen, L. A., de la Chapaelle, A., Spiegelman, B. M., and Eng, C. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol. Cell, 3: 799–804, 1999.
76. Cui, Y., Miyoshi, K., Claudio, E., Siebenlist, U. K., Gonzalez, F. J., Flaws, J., Wagner, K-U., and Hennighausen, L. Loss of the peroxisome proliferation-activated receptor gamma (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduce fertility. J. Biol. Chem. 277: 17830–17835, 20002.
77. Ikezoe, T., Kawano, S., Miller, C. W., Heaney, A., Williamson, E. A., Hisatake, J., Green, E., Hofmann, W., Taguchi, H., and Koeffler, H. P. Mutational analysis of the peroxisome proliferator activated receptor γ (PPARγ) gene in human malignancies. Cancer Res., 61: 5307–5310, 2001.
78. Barroso, I., Gurnell, M., Crowley, V. E., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D., Lewis, H., Schafer, A. J., Chatterjee, V. K., and O’Rahilly, S. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature (Lond.), 402: 880–884, 1999.
79. Valve, R., Sivenios, K., Miettinen, R., Pihlajamaki, J., Rissanen, A., Deeb, S. S., Auwerx, J., Vusitupa, M., and Laakso, M. Two polymorphisms in the peroxisome proliferator-activated receptor γgene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab., 84: 3708–3712, 1999.
80. Ek, J., Urhammer, S. A., Sorensen, T. I., Andersen, T., Auwerx, J., and Pedersen, O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia, 42: 892–895, 1999.
81. Mancini, F. P., Vaccaro, O., Sabatino, L., Tufano, A., Rivellese, A. A., Riccardi, G., and Colantuoni, V. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes, 48: 1466–1468, 1999.
82. Wang, M., Wise, S. C., Leff, T., and Su, T. Z. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γ. Diabetes, 48: 254–260, 1999.
83. Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y. H., Ricote, M., Glass C. K., Brewer, H. B., Jr., and Gonzalez, F. J. Conditional disruption of the peroxisome proliferatoractivated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol., 22: 2607–2619, 2002.
84. Abe, A., Kiriyama, Y., Hirano, M., Miura, T., Kamiya, H., Harashima, H., and Tokumitsu, Y. Troglitazone suppresses cell growth of KU812 cells independently of PPARγ. Eur. J. Pharmacol., 436: 7–13, 2002.
85. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., and Evans, R. M. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med., 7: 48–52, 2001.
86. Spiegelman, B. M. PPARγ in monocytes: less pain and gain? Cell, 93: 153-155, 1998.
87. Palakurthi, S. S., Aktas, H., Grubissich, L. M., Mortensen, R. M., and Halperin, J. A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γand mediated by inhibition of translation initiation. Cancer Res., 61: 6213–6218, 2001.
88. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M. G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IĸB kinase. Nature (Lond.), 403: 103–106, 2000.
89. Straus, D. S., Pascual, G., Li, M., Welch, J. S., Rocote, M., Hsiang, C. H., Sengchanthalangsy, L. L., Ghosh, G., and Glass, C. K. 15-deoxy-Δ(12,14)-prostaglandin J2 inhibits multiple steps in the NF-ĸB signaling pathway. Proc. Natl. Acad. Sci. USA, 97: 4844, 2000.